TIL · Instil Bio, Inc. · Exempt Offerings
$6.04
+0.25 (+4.32%)
At close · Oct 20
Return incl. dividend (before tax)
Going-concern doubt
— cleared Aug 13, 2026
The latest filing states the doubt was alleviated.
“As discussed above and in Note 10 to the accompanying condensed consolidated financial statements, the 2024 Loan is due in January 2027, for total principal of $85.6 million, which is in excess of cash, cash equivalents, and marketable securities on hand as of June 30, 2026, which we concluded is an indicator of substantial doubt about our ability to continue as a going concern. We concluded that management's plans, including Complex Therapeutics LLC's contractual right to exercise the extension option to January 2028, which is within Complex Therapeutics LLC's control, alleviate the conditions that raise substantial doubt about our ability to continue as a going concern.”View the 10-Q filed Aug 13, 2026
Market Cap
$39.27M
Shares
6.78M
Volume · Oct 20
98.11K
Avg daily vol (3M)
16.15K
Private capital raises reported to the SEC on Form D under Regulation D, showing the offering size, amount sold, minimum investment and number of investors. Public operating companies rarely raise capital this way, so this page is often empty.
| Filed | Type | Industry | Offering | Sold | Exemptions |
|---|---|---|---|---|---|
| 2021-02-23 | New | Biotechnology | $185,449,881 | $185,449,881 | 06b |
| 2020-08-05 | Amendment | Biotechnology | $25,000,000 | $25,000,000 | 06b |
| 2020-08-05 | New | Biotechnology | $515,917 | $515,917 | 06b |
| 2020-08-05 | New | Biotechnology | $170,199,973 | $170,199,973 | 06b |
Showing 1–4 of 4 filings